About Coiled-coil domain-containing protein 160
Coiled-coil domain-containing protein 160 (CCDC160) is a protein
from Homo sapiens identified by UniProt accession
A6NGH7, 325 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Coiled-coil domain-containing protein 160 |
| UniProt accession | A6NGH7 |
| Gene | CCDC160 |
| Organism | Homo sapiens |
| Length | 325 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (16)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.13
- genetic disorder · score 0.12
- isolated spina bifida · score 0.04
- spina bifida-hypospadias syndrome · score 0.04
- anencephaly 1 · score 0.03
- dysraphism-cleft lip/palate-limb reduction defects syndrome · score 0.03
- tropical spastic paraparesis · score 0.03
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10 · score 0.03
- insomnia measurement · score 0.02
- self reported educational attainment · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NGH7-F1 | alphafold | PREDICTED | 72.33 | — |
Amino-acid sequence (325 residues)
MDARRKHWKE NMFTPFFSAQ DVLEETSEPE SSSEQTTADS SKGMEEIYNL SSRKFQEESK FKRKKYIFQL NEIEQEQNLR ENKRNISKNE TDTNSASYES SNVDVTTEES FNSTEDNSTC STDNLPALLR QDIRKKFMER MSPKLCLNLL NEELEELNMK YRKIEEEFEN AEKELLHYKK EIFTKPLNFQ ETETDASKSD YELQALRNDL SEKATNVKNL SEQLQQAKEV IHKLNLENRN LKEAVRKLKH QTEVGNVLLK EEMKSYYELE MAKIRGELSV IKNELRTEKT LQARNNRALE LLRKYYASSM VTSSSILDHF TGDFF
Explore Coiled-coil domain-containing protein 160 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets